Video Experimental Relacionado
Updated: Jul 9, 2026
12:37
Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
Published on: February 9, 2016
Efectos de la lidocaína en la relación entre el umbral de desfibrilación y el límite superior de vulnerabilidad en
S L Topham1, Y M Cha, B B Peters
1Department of Medicine, University of California San Diego Medical Center 92103-8411.
Circulation
|March 1, 1992
Resumen
La lidocaína aumenta tanto el umbral de desfibrilación (DFT50) como el límite superior de vulnerabilidad (ULV50) en perros. Sin embargo, el ULV50 aumentó más que el DFT50, lo que sugiere que otros factores influyen en la desfibrilación.
Área de la Ciencia:
- Fisiología cardiovascular fisiología cardiovascular.
- Farmacología Farmacología.
Sus antecedentes:
- La relación entre el umbral de desfibrilación y el límite superior de vulnerabilidad es crucial para comprender la eficacia de la desfibrilación.
- La lidocaína es un medicamento antiarrítmico con efectos conocidos en la electrofisiología cardíaca.
Objetivo del estudio:
- Investigar los efectos de la lidocaína en el umbral de desfibrilación (DFT50) y el límite superior de vulnerabilidad (ULV50).
Principales métodos:
- Se utilizaron perros de pecho abierto para determinar el DFT50 y el ULV50 antes y durante la infusión de lidocaína.
- Se empleó el método de arriba abajo retrasado y la configuración de electrodos parche-parche.
- Se monitorearon los niveles séricos de lidocaína y los parámetros electrocardiográficos (intervalo QT, complejo QRS).
Principales resultados:
- La lidocaína aumentó significativamente tanto el ULV50 como el DFT50 en perros.
- ULV50 mostró un aumento mayor que DFT50 durante la infusión de lidocaína.
- La infusión salina normal no afectó el ULV50 o el DFT50.
Conclusiones:
- La administración de lidocaína eleva tanto el límite superior de vulnerabilidad como el umbral de desfibrilación.
- Los hallazgos apoyan el límite superior de la hipótesis de vulnerabilidad de la desfibrilación.
- El aumento desproporcionado en el ULV50 sugiere que factores adicionales influyen en los resultados de la desfibrilación durante el tratamiento con lidocaína.
Videos de Conceptos Relacionados
01:29Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...